RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-concept study

Parkinsonism and Related Disorders

Volumn 19, Issue 2, 2013, Pages 260-264

  Johnston, Tom H ^a,b   Huot, Philippe ^a,d   Damude, Sammie ^c   Fox, Susan H ^d   Jones, Steven W ^e   Rusche, James R ^e   Brotchie, Jonathan M ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Atuka Ltd   (Canada)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d TORONTO WESTERN HOSPITAL   (Canada)

^e REPLIGEN CORPORATION   (United States)

Author keywords

Dyskinesia; Epigenetics; Parkinson's disease; Primate

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N [6 (2 AMINOPHENYLAMINO) 6 OXYHEXYL] 4 METHYLBENZAMIDE; RGFP 109; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALLITHRIX; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEACETYLATION; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSKINESIA; ENZYME INHIBITION; FEMALE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION;

ANIMALS; ANTIPARKINSON AGENTS; CALLITHRIX; DYSKINESIA, DRUG-INDUCED; FEMALE; HISTONE DEACETYLASE INHIBITORS; LEVODOPA; PARKINSONIAN DISORDERS;

EID: 84873718850     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.07.001     Document Type: Article

References (29)

1. Voon V., Fernagut P.O., Wickens J., Baunez C., Rodriguez M., Pavon N., et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009, 8:1140-1149.
2. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000, 47:S2-S9. discussion S-11.
3. Hely M.A., Morris J.G., Reid W.G., Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005, 20:190-199.
4. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005, 57:17-26.
5. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J.A., et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 2007, 27:6995-7005.
6. Fasano S., Bezard E., D'Antoni A., Francardo V., Indrigo M., Qin L., et al. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A 2010.
7. Luger K., Mader A.W., Richmond R.K., Sargent D.F., Richmond T.J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997, 389:251-260.
8. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
9. Kazantsev A.G., Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008, 7:854-868.
10. Nicholas A.P., Lubin F.D., Hallett P.J., Vattem P., Ravenscroft P., Bezard E., et al. Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem 2008, 106:486-494.
11. Rai M., Soragni E., Chou C.J., Barnes G., Jones S., Rusche J.R., et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One 2010, 5:e8825.
12. Institute of Laboratory Animal Resources (U.S.) Guide for the care and use of laboratory animals 1996, Committee on Care and Use of Laboratory Animals N, U.S. Dept. of Health and Human Services, Public Health Service, Bethesda, Md.
13. Gomez-Ramirez J., Johnston T.H., Visanji N.P., Fox S.H., Brotchie J.M. Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2006, 21:839-846. Official Journal of the Movement Disorder Soceity.
14. Visanji N.P., Gomez-Ramirez J., Johnston T.H., Pires D., Voon V., Brotchie J.M., et al. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2006, 21:1879-1891.
15. Fox S.H., Henry B., Hill M., Crossman A., Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2002, 17:1180-1187.
16. Huot P., Johnston T.H., Lewis K.D., Koprich J.B., Reyes M.G., Fox S.H., et al. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. J Neurosci 2011, 31:7190-7198.
17. Johnston T.H., Millar Z., Huot P., Wagg K., Thiele S., Salomoncyzk D., et al. A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. FASEB J 2012, 26. 10.1096/fj.11-195016.
18. Sandi C., Pinto R.M., Al-Mahdawi S., Ezzatizadeh V., Barnes G., Jones S., et al. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol Dis 2011, 42:496-505.
19. Price P.A., Parkes J.D., Marsden C.D. Sodium valproate in the treatment of levodopa-induced dyskinesia. J Neurol Neurosurg Psychiatr 1978, 41:702-706.
20. Johannessen C.U. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000, 37:103-110.
21. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. Cell Mol Life Sci 2007, 64:2090-2103.
22. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978.
23. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276:36734-36741.
24. Schwartz C., Palissot V., Aouali N., Wack S., Brons N.H., Leners B., et al. Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. Int J Oncol 2007, 30:573-582.
25. Valentini A., Gravina P., Federici G., Bernardini S. Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther 2007, 6:185-191.
26. Hahnen E., Hauke J., Trankle C., Eyupoglu I.Y., Wirth B., Blumcke I. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin Investig Drugs 2008, 17:169-184.
27. Zhou W., Bercury K., Cummiskey J., Luong N., Lebin J., Freed C.R. Phenylbutyrate upregulates DJ-1 and protects neurons in cell culture and in animal models of Parkinson's disease. J Biol Chem 2011.
28. Vigushin D.M., Coombes R.C. Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets 2004, 4:205-218.
29. Acharya M.R., Sparreboom A., Venitz J., Figg W.D. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 2005, 68:917-932.